Background: Copeptin is a biomarker for brain injury. However,it is unclear whether it is discriminative regarding in-hospital major adverse events (IMAEs),including acute lung injury,acute traumatic coagulopathy,prog...Background: Copeptin is a biomarker for brain injury. However,it is unclear whether it is discriminative regarding in-hospital major adverse events (IMAEs),including acute lung injury,acute traumatic coagulopathy,progressive hemorrhagic injury and post-traumatic cerebral infarction,in patients with traumatic brain injury (TBI). This study was aimed at investigating the relationship between the serum copeptin level and occurrences of IMAEs. Methods: In this multicenter observational study,we recruited 173 severe TBI patients and 173 healthy controls. Serum levels of copeptin,interleukin-6,tumor necrosis factor-alpha,C-reactive protein,myelin basic protein,glial fibrillary astrocyte protein,S100B,neuron-specific enolase,phosphorylated axonal neurofilament subunit H,tau protein and ubiquitin carboxyl-terminal hydrolase L1 were quantified using available enzyme-linked immunosorbent assays. Areas under the receiver operating characteristic curves (AUCs) were estimated to determine and compare their discriminatory ability for IMAEs. Results: Patients had dramatically elevated levels of the afore-mentioned biomarkers,as compared with controls. In the discrimination of IMAEs,serum copeptin had a significantly higher AUC than serum interleukin-6,tumor necrosis factor-alpha and C-reactive protein and its AUC was similar to that of the Glasgow coma scale (GCS) score and the other remaining biomarkers mentioned above. Except copeptin,no other biomarkers could significantly improve the AUC of the GCS score. Conclusion: Serum copeptin levels combined with the GCS score might aid in discriminating IMAEs following TBI.展开更多
文摘Background: Copeptin is a biomarker for brain injury. However,it is unclear whether it is discriminative regarding in-hospital major adverse events (IMAEs),including acute lung injury,acute traumatic coagulopathy,progressive hemorrhagic injury and post-traumatic cerebral infarction,in patients with traumatic brain injury (TBI). This study was aimed at investigating the relationship between the serum copeptin level and occurrences of IMAEs. Methods: In this multicenter observational study,we recruited 173 severe TBI patients and 173 healthy controls. Serum levels of copeptin,interleukin-6,tumor necrosis factor-alpha,C-reactive protein,myelin basic protein,glial fibrillary astrocyte protein,S100B,neuron-specific enolase,phosphorylated axonal neurofilament subunit H,tau protein and ubiquitin carboxyl-terminal hydrolase L1 were quantified using available enzyme-linked immunosorbent assays. Areas under the receiver operating characteristic curves (AUCs) were estimated to determine and compare their discriminatory ability for IMAEs. Results: Patients had dramatically elevated levels of the afore-mentioned biomarkers,as compared with controls. In the discrimination of IMAEs,serum copeptin had a significantly higher AUC than serum interleukin-6,tumor necrosis factor-alpha and C-reactive protein and its AUC was similar to that of the Glasgow coma scale (GCS) score and the other remaining biomarkers mentioned above. Except copeptin,no other biomarkers could significantly improve the AUC of the GCS score. Conclusion: Serum copeptin levels combined with the GCS score might aid in discriminating IMAEs following TBI.
